6426 Journal of Medicinal Chemistry, 2007, Vol. 50, No. 25
Shimshoni et al.
Structural Analogues and Esters. Neuropharmacology 2000, 39, 254–
266.
(22) Bialer, M. Clinical Pharmacology of Valpromide. Clin. Pharmacokinet.
1991, 20, 114–122.
analysis (PDF). This material is available free of charge via the
(23) Hadad, S.; Bialer, M. Pharmacokinetic Analysis and Antiepileptic
Activity of N-Valproyl Derivatives of GABA and Glycine. Pharm.
Res. 1995, 12, 905–910.
References
(1) McNamara, J. O. Pharmacotherapy of the Epilepsies. In The Phar-
macological Basis of Therapeutics, 11th ed.; Brunton, L. L., Lazo,
J. S., Parker, K. L., Eds.; McGraw-Hill, New York, 2006; pp 501–
525.
(2) Bourgeois, F. D. B. Valproic Acid: Clinical Efficacy and Use in
Epilepsy. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H.,
Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams & Wilkins
Publishers, New York, 2002; pp 808–817.
(3) Koenig, S. A.; Buesing, D.; Longin, E.; Oehring, R.; Häussermann,
P.; Kluger, G.; Lindmayer, F.; Hanusch, R.; Degen, I.; Kuhn, H.; Samii,
K.; Jungck, A.; Brückner, R.; Seitz, R.; Boxtermann, W.; Weber, Y.;
Knapp, R.; Richard, H. H.; Weidner, B.; Kasper, J. M.; Haensch, C. A.;
Fitzek, S.; Hartmann, M.; Borusiak, P.; Müller-Deile, A.; Degenhardt,
V.; Korenke, G. C.; Hoppen, T.; Specht, U.; Gerstner, T. Valproic
Acid-Induced Hepatopathy: Nine New Fatalities in Germany from
1994 to 2003. Epilepsia 2006, 47, 2027–2031.
(4) Tomson, T.; Battino, D. Teratogenicity of Antiepileptic Drugs: State
of the Art. Curr. Opin. Neurol. 2005, 18, 135–140.
(5) Vajda, F. J.; O’Brien, T. J.; Hitchcock, A.; Graham, J.; Cook, M.;
Lander, C.; Eadie, M. J. Critical Relationship between Sodium
Valproate Dose and Human Teratogenicity: Results of the Australian
Register of Anti-Epileptic Drugs in Pregnancy. J. Clin. Neurol. 2004,
11, 854–858.
(24) Isoherranen, N.; Yagen, B.; Woodhead, J. H.; Spiegelstein, O.; Blotnik,
S.; Wilcox, S. K.; Finnell, R. H.; Bennett, D. G.; White, S. H.; Bialer,
M. Characterization of the Anticonvulsant Profile and Enantioselective
Pharmacokinetics of the Chiral Valproylamide Propylisopropyl Ac-
etamide in Rodents. Br. J. Pharmacol. 2003, 138, 602–613.
(25) Isoherranen, N.; White, S. H.; Klein, B. D.; Roeder, M.; Woodhead,
J. H.; Schuring, V.; Yagen, B.; Bialer, M. Pharmacokinetic-Pharma-
codynamic Relationship of (2S, 3S)-Valnoctamide and its Stereoisomer
(2R, 3S)-Valnoctamide in Rodent Models of Epilepsy. Pharm. Res.
2003, 20, 1293–1301.
(26) Spiegelstein, O.; Yagen, B.; Levy, R. H.; Finnell, R. H.; Bennett, G. D.;
Roeder, M.; Schuring, V.; Bialer, M. Stereoselective Pharmacokinetics
and Pharmacodynamics of Propylisopropylacetamide, a CNS-Active
Chiral Amide Analog of Valproic Acid. Pharm. Res. 1999, 16, 1582–
1588.
(27) Davidou, P. The Spectrum of Action of Valnoctamide in Daily
Psychiatric Practice. Toulouse Med. 1964, 65, 1127–1158.
(28) Applebaum, J.; Gayduk, J.; Agam, G.; Bersudsky, Y.; Belmaker, R. H.
Valnoctamide as Valproate Substitute with Low Teratogenic Potential:
Double Blind Controlled Clinical Trial. Bipolar Disorder 2005, 7
(29) Barel, S.; Yagen, B.; Schurig, V.; Soback, S.; Pisani, F.; Perucca, E.;
Bialer, M. Stereoselective Pharmacokinetic Analysis of Valnoctamide
in Healthy Subjects and in Patients with Epilepsy. Clin. Pharmacol.
Ther. 1997, 61, 442–449.
(30) Levi, M.; Yagen, B.; Bialer, M. Pharmacokinetics and Antiepileptic
Activity of Valproyl Hydroxamic Acid Derivatives. Pharm. Res. 1997,
14, 213–217.
(31) Hadad, S.; Bialer, M. Pharmacokinetic Analysis and Antiepileptic
Activity of Two New Isomers of N-Valproyl Glycinamide. Biopharm.
Drug Disposit. 1997, 18, 557–566.
(32) Isoherranen, N.; Woodhead, H. J.; White, H. S.; Bialer, M. Anticon-
vulsant Profile of Valrocemide (TV1901): A New Antiepileptic Drug.
Epilepsia 2001, 42, 831–836.
(33) Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Perucca,
E.; Tomson, T. Progress Report on New Antiepileptic Drugs: A
Summary of the Eighth Eilat Conference on New Antiepileptic Drugs
(EILAT VIII). Epilepsy Res. 2007, 73, 1–52.
(6) Sussman, N. M.; McLean, L. W., Jr. A Direct Hepatotoxic Effect of
Valproic Acid. JAMA. 1979, 242, 1173–1174.
(7) Zimmerman, H. J.; Ishak, K. G. Valproate-Induced Hepatic Injury:
Analysis of 23 Fatal Cases. Hepatology 1982, 2, 591–597.
(8) Nau, H.; Loscher, W. Pharmacological Evaluation of Various Me-
tabolites and Analogous of Valproic Acid: Teratogenic Potencies in
Mice. Fundam. Appl. Toxicol. 1986, 6, 669–676.
(9) Nau, H.; Hauck, R. S.; Ehlers, K. Valproic Acid Induced Neural Tube
Defects in Mouse and Human: Aspects of Chirality, Alternative Drug
Development, Pharmacokinetics and Possible Mechanisms. Pharmacol.
Toxicol. 1991, 69, 310–321.
(10) Hauck, R. S.; Nau, H.; Elmazar, M. M. On the Development of
Alternative Antiepileptic Drugs. Lack of Enantioselectivity of the
Anticonvulsant Activity, in Contrast to Teratogenicity, of 2-n-propyl-
4-pentenoic Acid and 2-n-propyl-4-pentynoic Acid, Analogues of the
Anticonvulsant Drug Valproic Acid. Naturwissenschaften 1991, 78,
272–274.
(34) Spielman, M. A.; Geiszler, A. O.; Close, W. J. Anticonvulsant Drugs,
II. Some Acetyureas. J. Am. Chem. Soc. 1948, 70, 4189–4191.
(35) Tantisira, B.; Tantisira, M. H.; Patarapanich, C.; Sooksawate, T.;
Chunngam, T. Preliminary Evaluation of Anticonvulsant Activity of
a Valproic Acid Analogue: N-(2-propylpentanoyl)urea. Res. Commun.
Mol. Pathol. Pharmacol. 1997, 97, 151–164.
(36) Winkler, I.; Sobol, E.; Yagen, B.; Steinmman, A.; Devor, M; Bialer,
M. Efficacy of Antiepileptic Tetramethylcyclopropyl Analogues of
Valproic Acid Amides in a Rat Model of Neuropathic Pain. Neurop-
harmacology 2005, 49, 1110–1120.
(37) Sobol, E.; Bialer, M.; Yagen, B. Tetramethylcyclopropyl Analogue
of a Leading Antiepileptic Drug, Valproic Acid. Synthesis and
Evaluation of Anticonvulsant Activity of its Amide Derivatives.
J. Med. Chem. 2004, 47, 4316–4326.
(38) Sobol, E.; Yagen, B.; White, H. S.; Wilcox, K. S.; Lamb, J. G.; Pappo,
O.; Wlodarczyk, B. J.; Finnell, R. H.; Bialer, M. Preclinical Evaluation
of 2,2,3,3-Tetramethylcyclopropanecarbonylurea, a Novel, Second
Generation to Valproic Acid, Antiepileptic Drug. Neuropharmacology
2006, 51, 933–946.
(11) Isoherranen, N.; Yagen, B.; Bialer, M. New CNS-Active Drugs Which
Are Second-Generation Valproic Acid: Can They Lead to the
Development of a Magic Bullet. Curr. Opin. Neurol. 2003, 16, 203–
211.
(12) Loscher, W.; Nau, H. Pharmacological Evaluation of Various Me-
tabolites and Analogues of Valproic Acid. Neuropharmacolgy. 1985,
24, 427–435.
(13) Liu, M. J.; Pollack, G. M. Pharmacokinetics and Pharmacodynamics
of Valproate Analogues in Rats: IV. Antiepileptic Action and
Neurotoxicity of Octanoic Acid, Cyclohexanecarboxylic Acid, and
1-Methyl-1-Cyclohexanecarboxylic Acid. Epilepsia 1994, 35, 234–
243.
(14) Morre, M.; Keane, P. E.; Vernieres, J. C.; Simiand, J.; Roncucci, R.
Valproate: Recent Findings and Perspectives. Epilepsia 1984, 25
(Suppl. 1), S5–S9.
(15) Keane, P. E.; Simiand, J.; Mendes, E.; Santucci, V.; Morre, M. The
Effects of Analogues of Valproic Acid on Seizures Induced by
Pentylenetetrazole and GABA Content in Brain of Mice. Neurophar-
macology 1983, 22, 875–879.
(39) Isoherranen, N.; White, H. S.; Finnell, R. H.; Yagen, B.; Woodhead,
J. H.; Bennett, G. D.; Wilcox, K. S.; Barton, M. E.; Bialer, M.
Anticonvulsant Profile and Teratogenicity of N-Methyl-Tetramethyl-
cyclopropyl Carboxamide: A New Antiepileptic Drug. Epilepsia 2002,
43, 115–126.
(40) Pfeffer, P. E.; Silbert, L. S.; Chirinko, J. M., Jr. R Anions of Carboxylic
Acids. II. The Formation and Alkylation of R-Metalated Aliphatic
Acids. J. Org. Chem. 1972, 37, 451–458.
(41) Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R.
Vogel’s Textbook of Practical Organic Chemistry; Prentice Hall: New
York, 1989; pp 720–723.
(42) Spiegelstein, O.; Bialer, M.; Radatz, M.; Nau, H.; Yagen, B.
Enantioselective Synthesis and Teratogenicity of Propylisopropyl
Acetamide, a CNS-Active Chiral Amide Analogue of Valproic Acid.
Chirality 1999, 11, 645–650.
(16) Bojic, U.; Elmazar, M. M. A.; Hauck, R. S.; Nau, H. Further Branching
of Valproate-Related Carboxylic Acids Reduces the Teratogenic
Activity, but not the Anticonvulsant Effect. Chem. Res. Toxicol. 1996,
9, 866–870.
(17) Abbott, S. F.; Acheampong, A. A. Quantitative Structure-Anticon-
vulsant Activity Relationships of Valproic Acid, Related Carboxylic
Acids and Tetrazoles. Neuropharmacology 1988, 27, 287–294.
(18) Badir, K.; Haj-Yehia, A.; Vree, B. T.; Van Der Kleijn, E.; Bialer, M.
Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric
Prodrugs of Valproic Acid. Pharm. Res. 1991, 8, 750–753.
(19) Haj-Yehia, A.; Bialer, M. Structure-Pharmacokinetic Relationships in
a Series of Valpromide Derivatives with Antiepileptic Activity. Pharm.
Res. 1989, 6, 683–689.
(20) Haj-Yehia, A.; Bialer, M. Structure-Pharmacokinetic Relationships in
a Series of Short Fatty Acid Amides that Possess Anticonvulsant
Activity. J. Pharm. Sci. 1990, 79, 719–724.
(21) Redecker, C.; Altrup, U.; Hoppe, D.; Dusing, R.; Speckmann, E.-J.
Effects of Valproate Derivatives I. Antiepileptic Efficacy of Amides,
(43) Katz, J.; Finestone, S. C.; Peppas, M. T.; Fine, J. A Double-Blind
Evaluation of Capuride (Pacinox ) as Presurgical Aid to Sleep. Curr.
Ther. Res. 1970, 12, 255–260.